natgillin/translations-raw huggingface dataset:
Depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further. 
Polako i jednolično pritišćite klip sve dok ne primijenite cijelu dozu i dok se klip ne može dalje potisnuti.
In clinical trials, 97% of patients who responded had a complete response at doses ≤ 24 μg/kg/day. 
U kliničkim je ispitivanjima 97 % bolesnika s odgovorom imalo potpuni odgovor na doze
1995 - 2000b a Analysis includes studies involving BM transplant during this period; some studies used GM-CSF b Analysis includes patients receiving BM transplant during this period 
Međunarodno retrospektivno ispitivanje (2006) 1995 - 2000b a Analiza uključuje ispitivanja presatka koštane srži tijekom tog razdoblja; neka su ispitivanja koristila
Hyperuricaemia Blood uric acid increased 
Hiperuricemija Povišena mokraćna kiselina u krvi
In patients undergoing a stem cell or bone marrow transplant, Graft versus Host Disease (GvHD) may occur- this is a reaction of the donor cells against the patient receiving the transplant; signs and symptoms include rash on the palms of your hands or soles of your feet and ulcer and sores in your mouth, gut, liver, skin, or your eyes, lungs, vagina and joints. 
Graft versus Host Disease - GvHD) - to je reakcija stanica davatelja na bolesnika koji prima presadak; znakovi i simptomi uključuju osip na dlanovima ili tabanima te vrijed/čir i rane u ustima, crijevu, jetri, koži ili očima, plućima, vagini i zglobovima.
Filgrastim HEXAL must not be diluted with sodium chloride solution. 
Filgrastim HEXAL se ne smije razrijediti otopinama natrijevog klorida.
Dizziness may occur following the administration of filgrastim (see section 4.8). 
Nakon primjene filgrastima može doći do omaglice (vidjeti dio 4.8).
In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1 - 2 days after initiation of filgrastim therapy. 
Prolazno povećanje broja neutrofila u bolesnika koji primaju citotoksičnu kemoterapiju obično se uočava 1 - 2 dana nakon početka terapije filgrastimom.
• pain and swelling of the joints, similar to gout (pseudogout) 
• bolovi u zglobovima i oticanje zglobova slično gihtu (pseudogiht)
* recombinant methionylated human granulocyte-colony stimulating factor (G-CSF) produced in E. coli by recombinant DNA technology. 
proizveden u E. coli tehnologijom rekombinantne DNK.
Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy. 
Podaci iz kliničkih studija u pedijatrijskih bolesnika sugeriraju da su sigurnost i djelotvornost filgrastima slični u odraslih i djece koja primaju citotoksičnu kemoterapiju.
• to increase the number of white blood cells after a bone marrow transplant to help prevent infections; 
• za povećanje broja bijelih krvnih stanica nakon transplantacije koštane srži kako bi se spriječile infekcije;
The most commonly reported adverse reactions are pyrexia, musculoskeletal pain (which includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain), anaemia, vomiting, and nausea. 
Najčešće prijavljivane nuspojave su vrućica, mišićno-koštana bol (što uključuje koštanu bol, bol u leđima, artralgiju, mijalgiju, bol u ekstremitetima, mišićno-koštanu bol, mišićno-koštanu bol u prsištu, bol u vratu), anemiju, povraćanje i mučninu.
The most serious adverse reactions that may occur during filgrastim treatment include: anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease. 
Najozbiljnije nuspojave do kojih može doći tijekom terapije filgrastimom obuhvaćaju: anafilaktičku reakciju, ozbiljne plućne štetne događaje (uključujući intersticijsku bolest pluća i sindrom akutnog respiratornog distresa), sindrom povećane propusnosti kapilara, splenomegaliju/rupturu slezene, prijelaz u leukemiju ili mijelodisplastični sindrom kod bolesnika s teškom kroničnom neutropenijom,
Dilution to a final concentration < 0.2 MU/ml (2 μg/ml) is not recommended at any time. 
Nikada se ne preporučuje razrjeđivanje do konačne koncentracije < 0,2 MU/ml (2 μg/ml).
Acute respiratory distress syndromea Respiratory failurea 
Sindrom akutnog respiratornog distresaa
The recommended starting dose is 1.2 MU/kg/day (12 μg/kg/day) as a single dose or in divided doses. 
Preporučena početna doza je 1,2 MU/kg/dan (12 μg/kg/dan) u obliku jedne ili više doza.
The first dose of filgrastim should be administered at least 24 hours following cytotoxic chemotherapy and at least 24 hours after bone marrow infusion. 
Prvu dozu filgrastima treba primijeniti najmanje 24 sata nakon citotoksične kemoterapije i najmanje 24 sata nakon infuzije koštane srži.
Generally asymptomatic cases of splenomegaly and cases of splenic rupture have been reported in patients and normal donors following administration of filgrastim. 
Obično asimptomatski slučajevi splenomegalije i slučajevi rupture slezene zabilježeni su u bolesnika i zdravih davatelja nakon primjene filgrastima.
Some patients may respond very rapidly and with a considerable increase in neutrophil count to the initial dose of filgrastim. 
U nekih bolesnika odgovor na početnu dozu filgrastima može nastupiti vrlo brzo i uz znatno povećanje broja neutrofila.
• unusual change in the urine 
• neuobičajena promjena u mokraći • smanjenje gustoće kostiju
Special care should be taken in the diagnosis of SCNs to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia, and myeloid leukaemia. 
Poseban oprez potreban je kod dijagnoze teških kroničnih neutropenija kako bi ih se razlikovalo od drugih krvotvornih poremećaja, kao što su aplastična anemija, mijelodisplazija ili mijeloična leukemija.
Leukocytosis (WBC > 50 x 109/l) was observed in 41% of normal donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4). 
Leukocitoza Leukocitoza (leukociti > 50 x 109/l) je primijećena u 41 % normalnih davatelja, dok je prolazna trombocitopenija (trombociti < 100 x 109/l) nakon filgrastima i leukafereze primijećena u 35 %
In patients treated with myeloablative therapy followed by bone marrow transplantation 
Kod bolesnika liječenih mijeloablativnom terapijom nakon koje slijedi presađivanje koštane srži
Once the neutrophil nadir has been passed, the daily dose of filgrastim should be titrated against the neutrophil response as follows: 
Nakon što prođe smanjenje broja neutrofila na najnižu vrijednost, dnevna doza filgrastima treba se titrirati prema odgovoru neutrofila na sljedeći način:
Physicians should use caution when prescribing filgrastim in patients with sickle cell trait or sickle cell disease. 
Liječnici trebaju s oprezom propisivati filgrastim u bolesnika s nasljednim obilježjem srpastih stanica ili s bolesti srpastih stanica.
For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation Posology 
Za mobilizaciju PBPC-ova kod zdravih donora prije transplantacije alogenim PBPC-ovima
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive treatments. 
Liječenje samo filgrastimom ne isključuje trombocitopeniju i anemiju zbog mijelosupresivnog liječenja.
There have been reports of GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 4.4 and 5.1). 
Zabilježeni su slučajevi reakcija presatka protiv primatelja (GvHD) i smrtni ishodi u bolesnika koji su primali G-CSF nakon alogene transplantacije koštane srži (vidjeti dijelove 4.4 i 5.1).
The needle safety guard will cover the needle when releasing the plunger. 
Sigurnosna zaštita za iglu pokrit će iglu kad otpustite klip.
Excipient with known effect Each ml of solution contains 50 mg sorbitol (E420). 
Jedan ml otopine sadrži 50 mg sorbitola (E420).
Discontinue filgrastim 
Prekinuti primjenu filgrastima
In patients with known bone marrow infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia. 
U bolesnika u kojih se potvrdi da je infekcija ili zloćudna bolest infiltrirala koštanu srž treba razmotriti odgovarajuću terapiju za liječenje osnovne bolesti uz primjenu filgrastima zbog liječenja neutropenije.
A subset of approximately 12% of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation. 
bolesnika koji su na početku imali normalne citogenetske nalaze kasnije su, na rutinski ponavljanim pregledima, otkrivene abnormalnosti, uključujući monosomiju
One retrospective European study evaluating the use of G-CSF after allogeneic bone marrow transplantation in patients with acute leukaemias suggested an increase in the risk of GvHD, treatment related mortality (TRM) and mortality when G-CSF was administered. 
Jedno retrospektivno europsko ispitivanje koje je procjenjivalo primjenu G-CSF nakon alogene transplantacije koštane srži u bolesnika s akutnim leukemijama ukazalo je na povećani rizik od GvHD,
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy. 
Liječenje samo filgrastimom ne isključuje pojavu trombocitopenije i anemije zbog mijelosupresivne kemoterapije.
PBPC mobilisation e Adverse events with higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy c. 
e Nuspojave s povećanom učestalošću u bolesnika koji primaju filgrastim u usporedbi s placebom te povezane s posljedicama osnovne zloćudne bolesti ili citotoksične kemoterapije c.
These autologous PBPCs may be harvested and infused after high-dose cytotoxic therapy, either in place of, or in addition to bone marrow transplantation. 
Ove autologne progenitorske stanice iz periferne krvi mogu se sakupiti i dati infuzijom nakon visokih doza citotoksične terapije bilo umjesto presađivanja koštane srži ili uz presađivanje koštane srži.
Kidney injury has been seen in patients who received filgrastim. 
Oštećenje bubrega zna se opaziti u bolesnika koji primaju filgrastim.
Filgrastim HEXAL contains no preservative. 
Filgrastim HEXAL ne sadrži konzervans.
Special precautions in patients with HIV infection 
Posebne mjere opreza u bolesnika s HIV infekcijom Broj krvnih stanica
Established cytotoxic chemotherapy 
Utvrđena citotoksična kemoterapija
• urinary tract infection 
Infekcija urinarnog trakta
Further dose adjustment may be necessary, as determined by the patient's ANC, to maintain the neutrophil count at > 2.0 x 109/l. 
Možda u bolesnika bude potrebna daljnja prilagodba doze, što se određuje prema apsolutnom broju neutrofila, da bi se broj neutrofila održao na > 2,0 x 109/l.
You will normally receive your first dose of Filgrastim HEXAL at least 24 hours after your chemotherapy and at least 24 hours after receiving your bone marrow transplant. 
Uobičajeno je prvu dozu Zarzia primiti najmanje 24 sata nakon kemoterapije i najmanje 24 sata nakon transplantacije koštane srži.
• redness of the skin (erythema) 
• osip • crvenilo kože (eritem)
The subcutaneous route is preferred in most cases. 
U većini slučajeva prednost se daje supkutanom načinu primjene.
For maintaining normal neutrophil counts 
Da bi se održao odgovarajući broj neutrofila,
Filgrastim should be diluted in 20 ml of 5% glucose solution (see section 6.6). 
Filgrastim treba razrijediti u 20 ml 5-postotne otopine glukoze (vidjeti dio 6.6).
Clean the skin at the injection site using an alcohol wipe. 
Tupferom natopljenim alkoholom očistite kožu na mjestu primjene injekcije.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
Unutar svake skupine učestalosti nuspojave su prikazane prema ozbiljnosti padajućim redoslijedom.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - PRE-FILLED SYRINGE WITH A NEEDLE SAFETY GUARD 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKO PAKIRANJE - NAPUNJENA ŠTRCALJKA SA SIGURNOSNOM ZAŠTITOM ZA IGLU
How to store Filgrastim HEXAL 
Kako primjenjivati Filgrastim HEXAL
The recommended starting dose of filgrastim is 1.0 MU/kg/day (10 μg/kg/day). 
Preporučena početna doza filgrastima je 1,0 MU/kg/dan (10 μg/kg/dan).
Leukocytosisa 
Leukocitozaa
The recommended dose of filgrastim is 0.5 MU/kg/day (5 μg/kg/day). 
Preporučena doza filgrastima je 0,5 MU/kg/dan (5 μg/kg/dan).
Each pre-filled syringe contains 48 million units (equivalent to 480 micrograms) filgrastim in 0.5 ml (96 MU/ml). 
Jedna napunjena štrcaljka sadrži 48 milijuna jedinica (što odgovara 480 mikrograma) filgrastima u 0,5 ml (96 MU/ml).
These have generally occurred in patients with advanced malignant diseases, sepsis, taking multiple chemotherapy medications or undergoing apheresis (see section 4.4). 
bolesnika koji su uzimali kemoterapiju koja se sastoji od više lijekova ili u bolesnika na aferezi (vidjeti dio 4.4).
• soreness and swelling of the digestive tract lining which runs from the mouth to the anus 
• bolovi i oticanje sluznice probavnog sustava od usta do anusa (upala sluznice/mukozitis)
Astheniaa Malaisee Oedema peripherale 
Astenijaa Malaksaloste Periferni edemie
4 - 5 consecutive days allows a collection of ≥ 4 x 106 CD34+ cells/kg recipient body weight in the majority of the donors after two leukaphereses. 
U zdravih davatelja, doza od 1 MU/kg/dan (10 μg/kg/dan) primijenjena supkutano tijekom 4 - 5 uzastopnih dana omogućuje prikupljanje ≥ 4 x 106 CD34+ stanica/kg tjelesne težine primatelja kod većine davatelja nakon dvije leukafereze.
Infusion of PBPC accelerates haematopoietic recovery reducing the duration of risk for haemorrhagic complications and the need for platelet transfusions. 
smanjujući trajanje rizika od hemoragijskih komplikacija i potrebu za transfuzijama trombocita.
• plum-coloured, raised, painful sores on the limbs and sometimes the face and neck with a fever 
• upala krvnih žila u koži (kožni vaskulitis) • tamnoplavi, uzdignuti, bolni plakovi (promjene na koži) na ekstremitetima i katkad na licu i vratu s vrućicom (Sweetov sindrom)
Filgrastim HEXAL 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe Each ml of solution contains 96 million units (MU) (equivalent to 960 micrograms [μg]) filgrastim*. 
Filgrastim HEXAL 48 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki Jedan ml otopine sadrži 96 milijuna jedinica (MU) (što odgovara 960 mikrograma [μg]) filgrastima*.
For infusions filgrastim should be diluted in 20 ml of 5% glucose solution (see section 6.6). 
Za potrebe infuzije filgrastim treba razrijediti u 20 ml 5-postotne otopine glukoze (vidjeti dio 6.6).
Premature discontinuation of filgrastim therapy, prior to the time of the expected neutrophil nadir, is not recommended. 
Ne preporučuje se preuranjeni prekid terapije filgrastimom, tj. prije očekivanog smanjenja broja neutrofila na najnižu vrijednost.
Filgrastim HEXAL 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe EU/1/08/496/001 
Filgrastim HEXAL 30 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki EU/1/08/496/001
Cases of decreased bone density and osteoporosis have been reported in paediatric patients with severe chronic neutropenia receiving chronic treatment with filgrastim. 
Pedijatrijski bolesnici s teškom kroničnom neutropenijom Slučajevi smanjene gustoće kostiju i osteoporoze zabilježeni su u pedijatrijskih bolesnika s teškom kroničnom neutropenijom koji primaju kronično liječenje filgrastimom.
Long-term administration may be required to maintain the ANC > 2.0 x 109/l. 
Može biti potrebna dugotrajna primjena da bi se apsolutni broj neutrofila održao na > 2,0 x 109/l.
During intermittent dosing with 30 MU/day (300 μg/day) of filgrastim, there can be wide fluctuations in the patient's ANC over time. 
30 MU/dan (300 μg/dan) u bolesnika mogu tijekom vremena postojati velike fluktuacije apsolutnog broja neutrofila.
Each pre-filled syringe contains 30 million units (equivalent to 300 micrograms) filgrastim in 0.5 ml (60 MU/ml). 
Jedna napunjena štrcaljka sadrži 30 milijuna jedinica (što odgovara 300 mikrograma) filgrastima u 0,5 ml (60 MU/ml).
• enlargement of the liver (hepatomegaly) 
• bol u području usta • povećanje jetre (hepatomegalija)
Splenic rupturea Sickle cell anaemia with crisis 
Ruptura slezenea Anemija srpastih stanica s krizom
Filgrastim HEXAL 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe: Each pre-filled syringe contains 48 MU filgrastim in 0.5 ml, corresponding to 96 MU/ml - The other ingredients are glutamic acid, sorbitol (E420), polysorbate 80 and water for injections. 
Jedna napunjena štrcaljka sadrži 48 MU filgrastima u 0,5 ml, što odgovara 96 MU/ml - Pomoćne tvari su glutamatna kiselina, sorbitol (E420), polisorbat 80 i voda za injekcije.
Filgrastim HEXAL 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe EU/1/08/496/005 
Filgrastim HEXAL 48 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki EU/1/08/496/005
Pseudogout (chondrocalcinosis pyrophosphate) has been reported in patients with cancer treated with filgrastim. 
Pseudogiht (hondrokalcinoza pirofosfat) je prijavljen u bolesnika s malignom bolešću koji primaju filgrastim.
musculoskeletal chest pain, neck pain d Cases were observed in the post-marketing setting in patients undergoing bone marrow transplant or 
mišićno-koštanu bol u prsištu, bol u vratu d Nakon stavljanja lijeka u promet zabilježeni su slučajevi u bolesnika s transplantiranom koštanom srži ili mobilizacijom progenitorskih stanica iz periferne krvi (PBPC)
The first dose of filgrastim should be administered at least 24 hours after cytotoxic chemotherapy. 
Prva doza filgrastima ne smije se primijeniti prije nego što protekne barem 24 sata nakon citotoksične kemoterapije.
For PBPC mobilisation in normal donors, filgrastim should be administered at 1.0 MU/kg/day (10 μg/kg/day) for 4 - 5 consecutive days. 
Za mobilizaciju progenitorskih stanica iz periferne krvi u zdravih davatelja, filgrastim treba primjenjivati u dozi od 1,0 MU/kg/dan (10 μg/kg/dan) tijekom 4 - 5 uzastopnih dana.
Transient cytogenetic abnormalities have been observed in normal donors following G-CSF use. 
U zdravih davatelja primijećene su prolazne citogenetske abnormalnosti nakon primjene G-CSF.
Solution for injection or infusion in pre-filled syringe (injection or infusion). 
Otopina za injekciju ili infuziju u napunjenoj štrcaljki (injekcija ili infuzija) Bistra, bezbojna do svijetložuta otopina.
Accidental exposure to freezing temperatures does not adversely affect the stability of Filgrastim HEXAL. 
Slučajno izlaganje niskim temperaturama neće štetno utjecati na stabilnost lijeka Filgrastim HEXAL.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE / PRE-FILLED SYRINGE WITH A NEEDLES SAFETY GUARD 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NAPUNJENA ŠTRCALJKA / NAPUNJENA ŠTRCALJKA SA SIGURNOSNOM ZAŠTITOM ZA IGLU
The recommended starting dose is 0.5 MU/kg/day (5 μg/kg/day) as a single dose or in divided doses. 
Preporučena početna doza je 0,5 MU/kg/dan (5 μg/kg/dan) u obliku jedne ili više doza.
Clinical trials with filgrastim have included a small number of elderly patients but special studies have not been performed in this group and therefore specific dosage recommendations cannot be made. 
No, posebna ispitivanja nisu provedena za tu skupinu pa se stoga ne mogu dati posebne preporuke za doziranje.
Complete blood cell counts with differential and platelet counts, and an evaluation of bone marrow morphology and karyotype should be performed prior to treatment. 
Prije liječenja potrebno je napraviti kompletnu krvnu sliku s diferencijalnom krvnom slikom i brojem trombocita, kao i procjenu morfologije koštane srži i kariotipa.
The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation. 
Vrućica nije trajala kraće u bolesnika koji su primali mijeloablativnu terapiju prije presađivanja koštane srži.
Filgrastim HEXAL 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe: Each pre-filled syringe contains 30 MU filgrastim in 0.5 ml, corresponding to 60 MU/ml. 
Filgrastim HEXAL 30 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki: Jedna napunjena štrcaljka sadrži 30 MU filgrastima u 0,5 ml, što odgovara 60 MU/ml.
However, for a sustained therapeutic response, filgrastim therapy should not be discontinued before the expected nadir has passed and the neutrophil count has recovered to the normal range. 
terapija filgrastimom ne smije se prekinuti prije nego što se broj neutrofila nakon očekivanog smanjenja na najniže vrijednosti ne oporavi do normalnog raspona vrijednosti.
Filgrastim HEXAL 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe Each ml of solution contains 60 million units (MU) (equivalent to 600 micrograms [μg]) filgrastim*. 
Filgrastim HEXAL 30 MU/0,5 ml otopina za injekciju ili infuziju u napunjenoj štrcaljki Jedan ml otopine sadrži 60 milijuna jedinica (MU) (što odgovara 600 mikrograma [μg]) filgrastima*.
Filgrastim HEXAL works by encouraging the bone marrow to produce more white blood cells. 
HEXAL djeluje poticanjem koštane srži da proizvodi više bijelih krvnih stanica.
In clinical studies and the post-marketing setting pulmonary adverse effects including interstitial lung disease, pulmonary oedema, and lung infiltration have been reported in some cases with an outcome of respiratory failure or acute respiratory distress syndrome (ARDS), which may be fatal (see section 4.4). 
U kliničkim ispitivanjima te u razdoblju nakon stavljanja lijeka u promet prijavljeni su plućne nuspojave, uključujući intersticijsku bolest pluća, plućni edem i plućnu infiltraciju, u nekim slučajevima s ishodom respiratornog zatajenja ili sindroma akutnog respiratornog distresa (ARDS),
The recommended dose of filgrastim for PBPC mobilisation when used alone is 1.0 MU/kg/day (10 μg/kg/day) for 5 - 7 consecutive days. 
Preporučena doza filgrastima za mobilizaciju progenitorskih stanica iz periferne krvi kod samostalne primjene iznosi 1,0 MU/kg/dan (10 μg/kg/dan) tijekom 5 - 7 uzastopnih dana.
Each pre-filled syringe contains 48 MU (equivalent to 480 μg) filgrastim in 0.5 ml. 
Jedna napunjena štrcaljka sadrži 48 MU (što odgovara 480 μg) filgrastima u 0,5 ml.
Each pre-filled syringe contains 30 MU (equivalent to 300 μg) filgrastim in 0.5 ml. 
Jedna napunjena štrcaljka sadrži 30 MU (što odgovara 300 μg) filgrastima u 0,5 ml.
Dose adjustment 
Prilagodbe doze:
Bronchitis Upper respiratory tract infection Urinary tract infection 
Bronhitis Infekcija gornjih dišnih putova
The symptoms experienced included fever, abdominal pain, malaise, back pain and inflammatory markers (e.g. C-reactive protein and white blood cell count) were raised. 
U zdravih osoba i bolesnika oboljelih od raka nakon primjene G-CSF-a zabilježen je aortitis, čiji su simptomi uključivali vrućicu, bol u abdomenu, malaksalost, bol u leđima i povišene upalne markere (npr. C-reaktivni protein i broj leukocita).
• generally feeling unwell (malaise) 
• opća slabost (astenija) • opće loše osjećanje (malaksalost)
Myelodysplastic syndrome or Chronic myeloid leukemia The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome, or chronic myelogenous leukaemia have not been established. 
Nije utvrđena sigurnost i djelotvornost primjene filgrastima u bolesnika s mijelodisplastičnim sindromom ili kroničnom mijeloičnom leukemijom.
Patients with a recent history of lung infiltrates or pneumonia may be at higher risk. 
Taj rizik može biti povećan u bolesnika koji su nedavno imali plućne infiltrate ili pneumoniju.